title: Drug-eluting stent implantation in patients with acute coronary syndrome - the Activity of Platelets after Inhibition and Cardiovascular Events: Optical Coherence Tomography (APICE OCT) study.
abstract: OBJECTIVE
  To our knowledge, no randomised study has compared rates of uncovered stent struts in everolimus (EES) vs. new-generation zotarolimus-eluting (ZES-R) stents in acute coronary syndrome (ACS). The aim of our study was to evaluate the completeness of neointimal coverage with optical coherence tomography (OCT) in ACS patients treated with drug-eluting stents (DES) comparing EES versus new-generation ZES-R.
  
  
  RESULTS
  All eligible ACS patients admitted to four Italian centres with a clinical indication for culprit lesion intervention were randomised 1:1 to EES or ZES-R. The primary study endpoint was the percentage of uncovered stent struts evaluated by optical coherence tomography (OCT) at six months. Secondary endpoints were the percentage of malapposed stent struts, percent neointimal hyperplasia cross-sectional area (CSA) and major adverse cardiac events (MACE) at six months. A total of 60 patients were randomised to EES (n=29) or ZES-R (n=31). No differences were observed in baseline characteristics between the two groups. Overall, 31.7% presented with STEMI, of which 68.4% were anterior. The other patients comprised 41.7% NSTEMI and 26.7% troponin-negative ACS. A mean of 1.3±0.6 lesions were treated per patient, with a mean of 1.3±0.5 stents per lesion. At 30 days there was one sudden death. Six-month OCT analysis was performed in 25 lesions in the EES group and in 24 lesions in the ZES-R group. There was no difference in the primary endpoint of uncovered stent struts between groups (EES 6.42% [3.27, 9.57] vs. ZES-R 7.07% [3.22, 10.92]; p=0.80). Furthermore, there were no differences between groups in the percentage of malapposed stent struts, either with (EES 1.19% [0.34, 2.04] vs. ZES-R 0.85% [0.40, 1.30]; p=0.49) or without coverage (EES 1.06% [0.12, 2.01] vs. ZES-R 0.24% [0.05, 0.44]; p=0.09). Percent neointima CSA was similar in both groups (EES 37.0% [18.6, 55.3] vs. ZES-R 26.6% [18.4, 34.8]; p=0.31). At six-month clinical follow-up, no additional patients died or suffered MI. There were four MACE in the EES group and one in the ZES-R group.
  
  
  CONCLUSIONS
  In our study, in patients presenting with ACS, both EES and ZES-R had low percentages of malapposed and uncovered stent struts at six-month OCT analysis.
authors: Interventional Cardiology Unit, San Raffaele Scientific Hospital, Milan, Italy.
authors: Alaide
authors: A
authors: Chieffo
authors: Gill Louise
authors: GL
authors: Buchanan
authors: Guido
authors: G
authors: Parodi
authors: Francesco
authors: F
authors: Versaci
authors: Renato Maria
authors: RM
authors: Bianchi
authors: Renato
authors: R
authors: Valenti
authors: Salvatore
authors: S
authors: Saccà
authors: Annalisa
authors: A
authors: Mongiardo
authors: Simonetta
authors: S
authors: Span
authors: Angela
authors: A
authors: Migliorini
authors: Carmen
authors: C
authors: Spaccarotella
authors: Bernhard
authors: B
authors: Reimers
authors: David
authors: D
authors: Antoniucci
authors: Ciro
authors: C
authors: Indolfi
authors: Angela
authors: A
authors: Ferrari
authors: Akiko
authors: A
authors: Maehara
authors: Gary S
authors: GS
authors: Mintz
authors: Antonio
authors: A
authors: Colombo
mesh_terms: D054058:Acute Coronary Syndrome / Q000209:etiology / Q000601:surgery*; D000368:Aged; D023903:Coronary Restenosis / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000150:complications / Q000473:pathology / Q000601:surgery*; D003331:Coronary Vessels / Q000473:pathology*; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D058426:Neointima / Q000473:pathology*; D062645:Percutaneous Coronary Intervention; D016037:Single-Blind Method; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D041623:Tomography, Optical Coherence
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; C489443:zotarolimus; D020123:Sirolimus